Sofiia E. Borovikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sofiia E. Borovikova has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Mikhail V. Shepelev
Center for Genome Research, Institute of Gene Biology, Russian Academy of Sciences, 34/5 Vavilova Str., 119334 Moscow, Russia
2 shared publications - Natalia A. Kruglova
Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences
2 shared publications - Anna V. Tvorogova
Institute of Gene Biology, Russian Academy of Sciences, Moscow 119334, Russia
1 shared publication - Dmitriy V. Mazurov
Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology Russian Academy of Sciences, 119334 Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9695
Modification of the HIV-1 Fusion Inhibitor 2P23 via N-Glycosylation Sites Enhances Its Cell Membrane Level and Antiviral Activity
HIV (Human immunodeficiency virus) gene therapy represents a promising strategy to suppress viral replication and potentially achieve long-term control of infection. One of the effective strategies is based on the generation of the genetically modified virus-resistant T cells by expressing peptide inhibitors of viral fusion on the cell membrane. These peptides, such as MT-C34 and 2P23, are derived from HIV gp41 protein and inhibit HIV entry into modified cells. We previously demonstrated in cell-to-cell viral transmission experiments that the 2P23 peptide showed lower protective activity than the MT-C34 peptide. In this study, we hypothesized that the difference in protective activity may arise from the differential N-glycosylation of the peptides. To test this, the 2P23 sequence was modified by introducing the N-glycosylation site (NDT) at the N-, C-, or both termini. These modifications significantly enhanced the plasma membrane expression and protective activity of the 2P23 peptide, with the NDT-2P23-NDT variant being the most potent. The validity of this peptide engineering approach was confirmed with the highly similar HP23L peptide, demonstrating an increased cell membrane expression and antiviral potency of the modified variant. Experiments with the N-glycosylation inhibitor tunicamycin provide indirect evidence that this effect is glycosylation-dependent. These findings suggest that introducing N-glycosylation sites is a versatile approach to improve the potency of membrane-bound antiviral peptides for HIV gene therapy.
- 29 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9695
Open AccessModification of the HIV-1 Fusion Inhibitor 2P23 via N-Glycosylation Sites Enhances Its Cell Membrane Level and Antiviral Activity
HIV (Human immunodeficiency virus) gene therapy represents a promising strategy to suppress viral replication and potentially achieve long-term control of infection. One of the effective strategies is based on the generation of the genetically modified virus-resistant T cells by expressing peptide inhibitors of viral fusion on the cell membrane. These peptides, such as MT-C34 and 2P23, are derived from HIV gp41 protein and inhibit HIV entry into modified cells. We previously demonstrated in cell-to-cell viral transmission experiments that the 2P23 peptide showed lower protective activity than the MT-C34 peptide. In this study, we hypothesized that the difference in protective activity may arise from the differential N-glycosylation of the peptides. To test this, the 2P23 sequence was modified by introducing the N-glycosylation site (NDT) at the N-, C-, or both termini. These modifications significantly enhanced the plasma membrane expression and protective activity of the 2P23 peptide, with the NDT-2P23-NDT variant being the most potent. The validity of this peptide engineering approach was confirmed with the highly similar HP23L peptide, demonstrating an increased cell membrane expression and antiviral potency of the modified variant. Experiments with the N-glycosylation inhibitor tunicamycin provide indirect evidence that this effect is glycosylation-dependent. These findings suggest that introducing N-glycosylation sites is a versatile approach to improve the potency of membrane-bound antiviral peptides for HIV gene therapy.
- Open Access
- 27 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12768
Efficient Genome Editing Using ‘NanoMEDIC’ AsCas12a-VLPs Produced with Pol II-Transcribed crRNA
Virus-like particles (VLPs) are an attractive vehicle for the delivery of Cas nuclease and guide RNA ribonucleoprotein complexes (RNPs). Most VLPs are produced by packaging SpCas9 and its sgRNA, which is expressed from the RNA polymerase III (Pol III)-transcribed U6 promoter. VLPs assemble in the cytoplasm, but U6-driven sgRNA is localized in the nucleus, which hinders the efficient formation and packaging of RNPs into VLPs. In this study, using the nuclease packaging mechanism of ‘NanoMEDIC’ VLPs, we produced VLPs with AsCas12a and exploited its ability to process pre-crRNA. This allowed us to direct crRNA in the cytoplasm as part of a Pol II-driven transcript where AsCas12a excised mature crRNA, thus boosting RNP incorporation into VLPs. CMV-driven crRNA increased Venus and CCR5 transgene knockout levels in 293 cells from 30% to 50–90% and raised the level of endogenous CXCR4 knockout in Jurkat T cells from 1% to 20%. Changing a single crRNA to an array of three or six identical crRNAs improved CXCR4 knockout rates by up to 60–70%. Compared to SpCas9-VLPs, the editing efficiencies of AsCas12a-VLPs were higher, regardless of promoter usage. Thus, we showed that AsCas12a and CMV-driven crRNA could be efficiently packaged into VLPs and mediate high levels of gene editing. AsCas12a-VLPs are a new and promising tool for the delivery of RNPs into mammalian cells that will allow efficient target genome editing and may be useful for gene therapy applications.
- 27 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12768
Open AccessEfficient Genome Editing Using ‘NanoMEDIC’ AsCas12a-VLPs Produced with Pol II-Transcribed crRNA
Virus-like particles (VLPs) are an attractive vehicle for the delivery of Cas nuclease and guide RNA ribonucleoprotein complexes (RNPs). Most VLPs are produced by packaging SpCas9 and its sgRNA, which is expressed from the RNA polymerase III (Pol III)-transcribed U6 promoter. VLPs assemble in the cytoplasm, but U6-driven sgRNA is localized in the nucleus, which hinders the efficient formation and packaging of RNPs into VLPs. In this study, using the nuclease packaging mechanism of ‘NanoMEDIC’ VLPs, we produced VLPs with AsCas12a and exploited its ability to process pre-crRNA. This allowed us to direct crRNA in the cytoplasm as part of a Pol II-driven transcript where AsCas12a excised mature crRNA, thus boosting RNP incorporation into VLPs. CMV-driven crRNA increased Venus and CCR5 transgene knockout levels in 293 cells from 30% to 50–90% and raised the level of endogenous CXCR4 knockout in Jurkat T cells from 1% to 20%. Changing a single crRNA to an array of three or six identical crRNAs improved CXCR4 knockout rates by up to 60–70%. Compared to SpCas9-VLPs, the editing efficiencies of AsCas12a-VLPs were higher, regardless of promoter usage. Thus, we showed that AsCas12a and CMV-driven crRNA could be efficiently packaged into VLPs and mediate high levels of gene editing. AsCas12a-VLPs are a new and promising tool for the delivery of RNPs into mammalian cells that will allow efficient target genome editing and may be useful for gene therapy applications.